{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Tenax Therapeutics, Inc.
Is Tenax Therapeutics, Inc. technically bullish or bearish?
As of June 18, 2025, the technical trend is mildly bullish due to daily moving averages and monthly MACD, but mixed signals from weekly MACD and Bollinger Bands suggest caution.
Who are in the management team of Tenax Therapeutics, Inc.?
As of March 2022, the management team of Tenax Therapeutics, Inc. includes Dr. Ronald Blanck (Independent Chairman), Mr. Anthony DiTonno (CEO), and Directors Mr. Steven Boyd, Mr. Keith Maher, Mr. James Mitchum, Mr. Gerald Proehl, and Mr. Gregory Pepin. They oversee the company's strategic direction and operations.
What does Tenax Therapeutics, Inc. do?
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing products for critical care, particularly acutely decompensated heart failure. It has a market cap of $23.56 million and reported a net profit loss of $10 million as of March 2025.
How big is Tenax Therapeutics, Inc.?
As of Jun 18, Tenax Therapeutics, Inc. has a market capitalization of 23.56 million and reported net sales of 0.00 million with a net profit of -24.22 million over the last four quarters. Shareholder's funds were 91.99 million, and total assets were 96.69 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
